Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials.

In addition, the use of JAK inhibitors was associated with a numerically lower all-cause mortality rate at day 14 than in the control group (1.5% [10/649] versus 3.1% [21/684]), but the difference did not reach statistical significance (OR, 0.48; 95% CI, 0.23–1.02, I 2 = 0).

also in 111,027 other papers